Li Xiuqi, Finberg Karin E
Department of Cell Biology, Harvard Medical School, Boston, MA, USA.
Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
Adv Exp Med Biol. 2025;1480:163-178. doi: 10.1007/978-3-031-92033-2_12.
Iron deficiency anemia (IDA) is estimated to affect over 1.2 billion people worldwide and is particularly common in children and reproductive-age women in low- and middle-income countries. Iron deficiency (ID) without anemia has an even higher prevalence. Absolute ID is caused by increased iron requirements, inadequate iron intake, impaired iron absorption, and chronic blood loss. ID triggers multiple adaptive physiological mechanisms, including modifications in cellular iron handling orchestrated by iron regulatory proteins, as well as alterations in systemic iron handling secondary to suppression of the iron regulatory hormone hepcidin. The laboratory diagnosis of ID is based on biochemical parameters and may be complicated during inflammatory conditions. ID is treated with oral or parenteral iron supplements, depending upon the severity of ID and its underlying cause(s). An improved understanding of systemic iron regulation has begun to inform oral iron dosing regimens and the selection of oral versus intravenous iron formulations for the management of ID.
据估计,全球有超过12亿人患有缺铁性贫血(IDA),在低收入和中等收入国家的儿童及育龄妇女中尤为常见。没有贫血的缺铁(ID)患病率更高。绝对缺铁是由铁需求增加、铁摄入不足、铁吸收受损以及慢性失血引起的。缺铁引发多种适应性生理机制,包括由铁调节蛋白精心调控的细胞铁处理变化,以及因铁调节激素铁调素受抑制而继发的全身铁处理改变。缺铁的实验室诊断基于生化参数,在炎症状态下可能会变得复杂。根据缺铁的严重程度及其潜在病因,可采用口服或胃肠外铁补充剂进行治疗。对全身铁调节的进一步了解已开始为口服铁给药方案以及用于缺铁管理的口服与静脉铁制剂的选择提供依据。